BiotechTube

MK-6837 + Pembrolizumab + Rescue Medications

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis

Trial Timeline

Jul 14, 2024 → Jul 13, 2027

NCT ID
NCT06460961

About MK-6837 + Pembrolizumab + Rescue Medications

MK-6837 + Pembrolizumab + Rescue Medications is a phase 1 stage product being developed by Merck for Neoplasm Metastasis. The current trial status is active. This product is registered under clinical trial identifier NCT06460961. Target conditions include Neoplasm Metastasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06460961Phase 1Active

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
AB0024Gilead SciencesPhase 1
32
TTI-237PfizerPhase 1
32
852APfizerPhase 1
32
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
LY2780301Eli LillyPhase 1
33
PemetrexedEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 1/2
41
IMC-3C5Eli LillyPhase 1
33
LY3295668Eli LillyPhase 1/2
41
Abemaciclib + ClarithromycinEli LillyPhase 1
33
Abemaciclib + FulvestrantEli LillyPhase 2
52
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
41
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
enzastaurinEli LillyPhase 2
52
enzastaurin + gemcitabineEli LillyPhase 2
52
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85